BCL6, a member of the BTB family of transcriptional repressors, promotes cancer progression (Fernando et al., 2019; Li et al., 2022; Zeng et al., 2023; Takamura et al., 2023) through participation in various cellular signal transduction pathways—including those involving proteins such as p53 (Hatzi and Melnick, 2014) —by binding to target gene promoters to suppress transcriptional programs (Cardenas et al., 2017). Here, BCL6 is linked to cancer.